SynthesisProbiotics and antimicrobial proteins2026
Effects of Probiotic and Synbiotic Supplementation on Glycemic Indices in Adult Individuals with Prediabetes and Type 2 Diabetes Mellitus: A Grade-Assessed Systematic Review and Dose-Response Meta-analysis of RCTs.
Synthesis in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Probiotics as modulators of the gut-derived incretin peptide axis in type 2 diabetes: GLP-1, GLP-2, and microbial metabolite signaling.Protoplasma · 2026Review
- Gut Microbiota as an Innovative Therapeutic Target in Cardiovascular Diseases from a Metabolic and Inflammatory Perspective.Biomedicines · 2026Review
- Modulation of gut-heart axis by synbiotic (Lactiplantibacillus plantarum M10 and Isomaltose) in high cholesterol diet induced atherosclerotic murine model.BMC microbiology · 2026Article
- Gut microbiota-host adaptive immune interactions in type 2 diabetes mellitus: mechanisms, disease progression, and microbiota-based therapeutic strategies.Frontiers in microbiology · 2026Review
- Evaluation of Potential Anti-Diabetic Synbiotic Formulation ofFoods (Basel, Switzerland) · 2025Article
- β-cell heterogeneity and molecular plasticity in type 2 diabetes: multi-omics perspectives and the role of gut microbiota.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotic and synbiotic supplementation has garnered attention for its potential to modulate metabolic parameters, including glycemic control, in individuals with prediabetes and type 2 diabetes mellitus (T2DM). This systematic review and dose-response meta-analysis aims to evaluate the effectiveness of these supplements on glycemic indices, synthesizing evidence from randomized controlled trials (RCTs) with grade-assessed methodologies. A comprehensive search of scientific databases was conducted from inception through January 2025 to identify RCTs assessing the effects of probiotic and synbiotic supplementation on glycemic indices, including fasting blood glucose (FBG), fasting insulin (FI), hemoglobin A1c (HbA1c), and homeostatic model assessment for insulin resistance (HOMA-IR). Eligible studies were screened; relevant data were extracted, and the quality of evidence was evaluated using the GRADE approach. Statistical analyses were performed using STATA to generate pooled results. The pooled analysis of 48 RCTs demonstrated that probiotics and synbiotics supplementation significantly decreased FBG (WMD: - 7.00 mg/dL), FI (WMD: - 1.72 µIU/mL), HbA1c levels (WMD: - 0.34%), and HOMA-IR (WMD: - 0.91), with a substantial heterogeneity across all outcomes (p < 0.001). Subgroup analyses indicated reductions in FBG, FI, HbA1c, and HOMA-IR across varying baseline characteristics, including glycemic levels, trial durations, and participant health status. Both probiotics and synbiotics were effective, with notable benefits for patients with T2DM, longer intervention durations, and higher baseline BMI. Meta-regression and dose-response analyses revealed no significant association between the duration of probiotic and synbiotic supplementation and changes in glycemic indices. Probiotic and synbiotic supplements significantly reduce FBG, FI, HbA1c, and HOMA-IR, leading to improvements in glycemic markers in individuals with prediabetes and T2DM. These supplements can be used as effective adjunctive strategies to enhance glycemic control, highlighting the promising role of gut microbiota modulation in diabetes management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.